PA-NEURAPTIVE
Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by nerve injuries, announced the appointment of industry R&D pioneer Robert (Bob) R. Ruffolo, Jr., Ph.D. to the company’s Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005443/en/
Robert R. Ruffolo, Ph.D. (Photo: Business Wire)
“On behalf of the Neuraptive Board and its directors, we are excited to welcome Bob to the board,” said Robert Radie, chairman, and chief executive officer of Neuraptive. “His extensive experience in drug research and development is a great addition to the Neuraptive board at this important time. We are fortunate to have attracted such an accomplished leader in our industry which speaks to the promise and potential of the work we are doing to transform the treatment of peripheral nerve injuries."
Dr. Ruffolo has over 40 years of research and development experience and is currently the Chairman of Aragen Biosciences, Inc. and Managing Director of Ruffolo Consulting, LLC, a consulting company for the pharmaceutical and biotechnology industries. Dr. Ruffolo is the retired President of Research and Development of Wyeth Pharmaceuticals, and Corporate Senior Vice President of the Wyeth Corporation (now Pfizer). He managed an R&D organization of 9,000 scientists with an annual budget in excess of $5 billion. Prior to Wyeth, Dr. Ruffolo held executive roles at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) and Lilly Research Laboratories. He earned his Ph.D. in Pharmacology and his B.S. in Pharmacy from The Ohio State University.
About Neuraptive
Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Philadelphia, PA. For more information, see www.neuraptive.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005443/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IN-IAC2.5.2024 20:01:27 CEST | Press release
The Indy Autonomous Challenge Returns to the Indianapolis Motor Speedway on September 6, 2024
TX-MARY-KAY2.5.2024 19:08:26 CEST | Press release
Mary Kay Inc. Announces Expansion Into Denmark, Strengthening Its Commitment to Women's Empowerment in Scandinavia
CT-INTERACTIVE-BROKERS2.5.2024 16:01:34 CEST | Press release
Interactive Brokers Launches Daily Options on the CAC 40® Index
AMRA-MEDICAL2.5.2024 15:36:33 CEST | Press release
AMRA Medical’s Muscle Composition Analysis Used to Evaluate the Effect of Liraglutide Treatment in Obesity
MA-BRIGHTCOVE2.5.2024 15:01:32 CEST | Press release
Brightcove Integrates New AWS-Powered Generative AI Solution to Enhance Its Award-Winning Customer Service
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom